Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.56 |
| ▸ | P4HB | P07237 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817086 | 0.87 | CYP2D6 (0.67) | CYP2D6CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL14456683 | 0.86 | KDM4E (0.67) | CYP2D6CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL8809190 | 0.86 | CYP3A4 (0.66) | CYP2D6CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL3498095 | 0.86 | CYP2D6 (0.56) | CYP2D6CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL4609435 | 0.85 | CYP3A4 (0.65) | CYP2D6CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL1290759 | 0.85 | CYP3A4 (0.65) | CYP2D6CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL20502739 | 0.84 | KDM4E (0.63) | CYP2D6CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL11282136 | 0.84 | OPRM1 (0.80) | CYP2D6CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL10500225 | 0.84 | CYP2D6 (0.63) | CYP2D6CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL26102667 | 0.84 | LMNA (0.69) | CYP2D6CYP3A4CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124428-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2024-04-18 | — | — | US | disclosed |
| EP-4263520-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022133529-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-06-30 | — | — | WO | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| CN-1019494-B | PROCESS FOR THE PRODUCTION OF CEPHEM DERIVATIVES AND INTERMEDIATES THERE OF | EISAI CO LTD (JP) | 1992-12-16 | — | — | CN | disclosed |
| US-5010188-A | Cephem derivatives | EISAI CO., LTD. (JP) | 1991-04-23 | — | — | US | disclosed |
| US-5008260-A | Bactericides | EISAI CO., LTD. (JP) | 1991-04-16 | — | — | US | disclosed |
| EP-0188255-B1 | CEPHEM DERIVATIVES | Eisai Co., Ltd. (JP) | 1991-04-03 | — | — | EP | disclosed |
| US-4748171-A | Cephem compounds having at the 3-position a (1,4-methylene-1-piperidinio)methyl group or a (1-quinuclidinio)methyl group | EISAI CO., LTD. (JP) | 1988-05-31 | — | — | US | disclosed |
| EP-0188255-A2 | Cephem derivatives | Eisai Co., Ltd. (JP) | 1986-07-23 | — | — | EP | disclosed |
| CN-86100852-A | Mould poison nuclear (Cephem) derivative of cephalo and intermediates preparation thereof | — | 1986-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124428-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | CYP2D6 1057/4885CYP3A4 1083/4885CYP2C9 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.